



---

Year: 2012

---

**Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC<sub>26981</sub>/NCIC\_CE.3trial**

Hegi, M E ; Janzer, R C ; Lambiv, W L ; Gorlia, T ; Kouwenhoven, M C M ; Hartmann, C ; von Deimling, A ; Martinet, D ; Besuchet Schmutz, N ; Diserens, A C ; Hamou, M F ; Bady, P ; Weller, M ; van den Bent, M J ; Mason, W P ; Mirimanoff, R O ; Stupp, R ; Mokhtari, K ; Wesseling, P

**Abstract:** Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of a central pathology review, we addressed the question if patients with GBM displaying distinct morphologic features respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were systematically recorded for 360 cases with particular focus on the presence of an oligodendroglioma-like component and respective correlations with outcome and relevant molecular markers. GBM with an oligodendroglioma-like component (GBM-O) represented 15% of all confirmed GBM (52/339) and was not associated with a more favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, significantly enriched for IDH1 mutations (19 vs. 3%,  $p = 0.003$ ) and EGFR amplifications (71 vs. 48%,  $p = 0.04$ ) compared with other GBM, while co-deletion of 1p/19q was found in only one case and the MGMT methylation frequency was alike (47 vs. 46%). Expression profiles classified most of the GBM-O into two subtypes, 36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-palisading necrosis (PPN) was associated with benefit from chemotherapy ( $p = 0.0002$ ), while no such effect was present in the absence of PPN ( $p = 0.86$ ). In the adjusted interaction model including clinical prognostic factors and MGMT status, PPN was borderline nonsignificant ( $p = 0.063$ ). Taken together, recognition of an oligodendroglioma-like component in an otherwise classic GBM identifies a pathogenetically mixed group without prognostic significance. However, the presence of PPN may indicate biological features of clinical relevance for further improvement of therapy.

DOI: <https://doi.org/10.1007/s00401-011-0938-4>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-64661>

Journal Article

Accepted Version

Originally published at:

Hegi, M E ; Janzer, R C ; Lambiv, W L ; Gorlia, T ; Kouwenhoven, M C M ; Hartmann, C ; von Deimling, A ; Martinet, D ; Besuchet Schmutz, N ; Diserens, A C ; Hamou, M F ; Bady, P ; Weller, M ; van den Bent, M J ; Mason, W P ; Mirimanoff, R O ; Stupp, R ; Mokhtari, K ; Wesseling, P (2012). Presence of an

oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC<sub>2</sub>6981/*NCIC\_CE.3trial*. *Acta Neuropathol* 2015; 129: 841 – 852.  
DOI: <https://doi.org/10.1007/s00401-011-0938-4>

Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value –

Central pathology review of the EORTC\_26981 / NCIC\_CE.3 trial

## **Authors**

Monika E Hegi<sup>1,2</sup>, Robert-Charles Janzer<sup>3</sup>, Wanyu L Lambiv<sup>1</sup>, Thierry Gorlia<sup>4</sup>, Mathilde CM Kouwenhoven<sup>5</sup>, Christian Hartmann<sup>6</sup>, Andreas von Deimling<sup>6</sup>, Danielle Martinet<sup>7</sup>, Nathalie Besuchet Schmutz<sup>7</sup>, Annie-Claire Diserens<sup>1</sup>, Marie-France Hamou<sup>1</sup>, Pierre Bady<sup>1,8</sup>, Michael Weller<sup>9</sup>, Martin J van den Bent<sup>5</sup>, Warren P Mason<sup>10</sup>, René-Olivier Mirimanoff<sup>11</sup>, Roger Stupp<sup>1</sup>, Karima Mokhtari<sup>12</sup>, and Pieter Wesseling<sup>13</sup>; on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups and the National Cancer Institute of Canada Clinical Trials Group

## **Affiliations**

<sup>1</sup>Department of Clinical Neurosciences, Lausanne University Hospital, Lausanne, Switzerland;

<sup>2</sup>National Center of Competence in Research Molecular Oncology, ISREC-SV-EPFL, Lausanne, Switzerland

<sup>3</sup>Department of Pathology, Lausanne University Hospital, Lausanne, Switzerland

<sup>4</sup>European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium

<sup>5</sup>Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands

<sup>6</sup>Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg and Clinical Cooperation Unit Neuropathology, DKFZ, Heidelberg, Germany,

<sup>7</sup>Department of Medical Genetics, Lausanne University Hospital, Lausanne, Switzerland

<sup>8</sup>Bioinformatics Core Facility, Swiss Institute for Bioinformatics, Lausanne

<sup>9</sup>Department of Neurology, University of Tübingen, Tübingen; Germany, and Department of Neurology, University Hospital Zurich, Zurich, Switzerland

<sup>10</sup>Princess Margaret Hospital, University of Toronto, Toronto, Canada

<sup>11</sup>Department of Radio-Oncology, Lausanne University Hospital, Lausanne, Switzerland

<sup>12</sup>Laboratoire de Neuropathologie R. Escourolle, Groupe Hospitalier Pitié-Salpêtrière, Paris, France;

<sup>13</sup>Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, and Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.

### **Corresponding author**

Monika E. Hegi, Laboratory of Brain Tumor Biology and Genetics, Neurosurgery, Centre Hospitalier Universitaire Vaudois (CHUV BH19-110), 46 rue du Bugnon, Lausanne 1011, Switzerland, Phone: +41-21-314-2582, Fax: +41-21-314-2587, Email: [Monika.Hegi@chuv.ch](mailto:Monika.Hegi@chuv.ch)

This work is dedicated to the memory of the late Dr. Robert-Charles Janzer who suddenly died in 2010. RCJ outlined the morphological analysis and coordinated central pathology review of this study.

## Abstract

Glioblastoma (GBM) is a morphologically heterogeneous tumor type with a median survival of only 15 months in clinical trial populations. However, survival varies greatly among patients. As part of central pathology review we addressed the question if patients with GBM displaying distinct morphologic features respond differently to combined chemo-radiotherapy with temozolomide. Morphologic features were systematically recorded for 360 cases with particular focus on presence of an oligodendroglioma-like component, and respective correlations with outcome, and relevant molecular markers. GBM with an oligodendroglioma-like component (GBM-O) represented 15% of all confirmed GBM (52/339) and was not associated with a more favorable outcome. GBM-O encompassed a pathogenetically heterogeneous group, significantly enriched for *IDH1* mutations (19% versus 3%,  $p=0.003$ ) and *EGFR* amplifications (71% versus 48%,  $p=0.04$ ) compared with other GBM, while co-deletion of 1p/19q was found in only one case, and the *MGMT* methylation frequency was alike (47% versus 46%). Expression profiles classified most of the GBM-O into two subtypes, 36% (5/14 evaluable) as proneural and 43% as classical GBM. The detection of pseudo-palisading necrosis (PPN) was associated with benefit from chemotherapy ( $p=0.0002$ ), while no such effect was present in the absence of PPN ( $p=0.86$ ). In the adjusted interaction model including clinical prognostic factors and *MGMT* status PPN was borderline non-significant ( $p=0.063$ ). Taken together, recognition of an oligodendroglioma-like component in an otherwise classic GBM identifies a pathogenetically mixed group without prognostic significance. However, the presence of PPN may indicate biological features of clinical relevance for further improvement of therapy.

## Key words

glioblastoma – glioblastoma with oligodendroglioma-like component – MGMT – IDH1 – EGFR - pathology – temozolomide – randomized trial – pseudopalisading necrosis – prognostic factors

## Introduction

The introduction of combined chemo-radiotherapy adding temozolomide concomitant and adjuvant to radiotherapy has modestly increased outcome of patients with newly diagnosed glioblastoma (GBM) [32] in particular in patients whose tumors contain an epigenetically inactivated *MGMT* gene [11]. However, outcome varies dramatically even in a homogenously treated patient population with a median survival of 15 months, 2- and 5-year survival rates of 27 and 11%, respectively [7,19,21,32]. Histopathologically GBM is a heterogeneous tumor type and distinct morphologic subtypes may benefit differently from combined chemo-radiotherapy. Furthermore, unequivocal separation of GBM and anaplastic astrocytomas from anaplastic oligo-astrocytic neoplasms is difficult. Previous reports suggested that distinct morphologic features present in GBM may have prognostic value, such as the presence of an oligodendroglioma-like component that was associated with better outcome in some studies, while the presence of necrosis has been reported as a negative prognostic factor [9,12,16,18,37].

Here we addressed the question whether particular morphologic features in GBM can identify clinically meaningful subgroups in this patient cohort treated homogenously with combined radio-chemotherapy that has become the standard of care. A specific goal was to investigate the clinical relevance of recognition of an oligodendroglioma-like component in GBM in tumors that had been diagnosed as GBM (all subtypes) by the initial local pathology assessment. The histopathological study was carried out as part of the central review performed in the phase III EORTC\_26981-22981-NCIC\_CE.3 trial for newly diagnosed GBM [32,33]. The results of this detailed histopathological review were

correlated with outcome and benefit from the new concomitant chemo-radiotherapy and in a subset of cases associated with genetic information including the *MGMT* methylation status, copy number aberrations (CNAs) of *EGFR*, *CDK4* and *MDM2*, combined loss of chromosomes 1p and 19q, and mutations of *IDH1*.

## **Patients and Methods**

### ***Patients***

Patients were enrolled in the phase III EORTC\_26981-22981-NCIC\_CE.3 trial [33] (ClinicalTrials.gov, number NCT00006353) between August 2000 and March 2002. Eligibility criteria have been detailed elsewhere [32] and comprised age between 18 and 70 years, histologically proven newly diagnosed GBM (WHO grade IV), and a WHO performance status of 0–2. Patients were randomized to either standard focal radiotherapy (RT) with a total dose of 60 Gy or concomitant chemotherapy of oral temozolomide (TMZ) at a daily dose of 75 mg/m<sup>2</sup> given 7 days per week during radiotherapy, followed by up to six cycles of adjuvant TMZ (150–200 mg/m<sup>2</sup>) for 5 days every 28 days. All patients had given written informed consent prior to entering the study, including for molecular analysis of their tumors. The study was approved by the local ethics committees.

### ***Pathology review***

Central review was performed jointly by three experienced neuropathologists (RCJ, KM, PW) according to WHO 2000 criteria [15] using a multiheaded microscope. H&E-stained

full sections were used for the evaluation. In most cases GFAP-, MIB-1- and a reticulin silver stain were available (collectively performed in Lausanne). Morphologic features were systematically recorded in a semi-quantitative manner and comprised cellular differentiation patterns, types of necrosis (large ischemic type vs. pseudopalisading necrosis), microvascular proliferation, and MIB-1 labeling index (see evaluation form, Supplementary Figure S1). In line with the WHO classification pseudopalisading necrosis (PPN) was defined as irregular, often serpiginous foci of necrosis surrounded by densely packed, radially oriented tumor cells. The agreement between the three pathologists was recorded. For this study, GBM with an oligodendroglioma-like component (GBM-O) were defined according to the following histopathological criteria: presence of at least 1 of 2 “major criteria” – ‘diffuse highly cellular and monotonous growth at low power magnification’, ‘monomorphous cell population’; and at least 2 of 3 “minor criteria” - ‘perinuclear halo-formation in tumor cells’, ‘rounded tumor cell nuclei with dense chromatin pattern’, ‘chickenwire architecture of tumor microvasculature’. The extent of these features in the viable tumor tissue was recorded (<25%, 25-75%, >75%). GBM with >25% of the tumor tissue showing oligodendroglioma-like component were subclassified as GBM-O (see Fig. 1 for some examples).

### ***Tissue Micro Array, Immunohistochemistry and Molecular Analysis***

Immunohistochemistry for GFAP and MIB-1, and histochemical reticulin staining were performed according to standard procedures on whole sections. A tissue micro array (TMA) was constructed comprising 130 patient samples where tumor blocks with



sufficient tissue were available as reported previously [21]. The TMA was used to screen for the most common IDH1 mutation (R132H) using the specific antibody mIDH1R132H (clone H14) [4] and for copy number aberrations (CNAs) of selected genes by FISH. FISH for *EGFR* was performed as described [34]. Two-color FISH assay was performed using a mixed 1p36/1q25 and 19p13/19q13 dual color probe set (Cat. No 32-231004, Vysis, Inc., Applied Biosystems, Downers Grove, IL) as described [31]. Samples showing sufficient FISH efficiency (~90% nuclei with signals) were evaluated. If possible, signals were scored in at least 200 non-overlapping, intact nuclei. Deletions of 1p and 19q were scored when at least 50% of tumor nuclei contained one signal. The following probes were used for *CDK4* and *MDM2*: KBI-10725 CD4K/SE12 (12q14); KBI-10717 MDM2/SE12 (12q15) (Kreatech Diagnostics, Amsterdam; NL).

The *MGMT* methylation status was determined and reported previously [11,32]. Expression of the *EGFRvIII* mutant, array comparative genomic hybridization (aCGH) data, and gene expression data was available for a subgroup of patients [17,21]. Additional *EGFR* amplification data was obtained by quantitative PCR as described [10]. Mutation analysis for *IDH1* and *IDH2* encompassing codon 132 and 172, respectively, was performed by direct Sanger sequencing.

## **Statistics**

The Fishers' exact test (for binary or nominal categorical data) and the Wilcoxon rank sum test (for continuous or ordinal categorical data) were used in the comparisons of patient and disease characteristics between subgroups. Survival analyses were performed with Kaplan Meier technique with log-rank statistics. The Cox Regression was

used for multivariate analyses. All Cox models were fit with age ( $\leq 50$ , 51-60,  $>60$ ), extent of surgery (total, partial, biopsy only), performance status (0, 1, 2), Mini Mental Score Examination ( $<27$ , 27-30) and *MGMT* methylation status (unmethylated, methylated). Pathological features significant at a 5% level in univariate analyses were included in the multivariate model. A treatment effect was assessed using Peto's heterogeneity test (predictive value). No adjustment for multiple testing was performed in these exploratory analyses. SAS version 9.2 was used for statistical analyses.

## **Results**

### ***Histological Diagnosis and Subclassification.***

Central review comprised histological analysis of 360 of 573 patients enrolled (central review of Canadian patients was performed independently). Baseline characteristics have been published previously [32] and sub-cohort patient characteristics are summarized in Supplemental Table S1. Overall the patient characteristics of this subset did not differ significantly from the overall study population, other than molecular markers that could be determined in patients who had undergone tumor resection in contrast to biopsy only. From the total of 360 cases reviewed 6 were considered undiagnosable due to insufficient tissue or quality of the sections. Fifteen (4.2%) tumors did not fulfill the criteria for GBM and comprised 4 anaplastic astrocytomas (WHO grade III; AA), 4 anaplastic oligoastrocytomas (WHO grade III, AOA), 1 anaplastic oligodendroglioma (WHO grade III; AO), 2 anaplastic ependymomas (WHO grade III), 2 pilocytic astrocytomas with malignant changes, 1 low grade glioma (WHO grade II), and 1 meningioma. Of the non-GBM tumors, 6 were in the RT and 9 in the RT/TMZ arm. The

remaining 339 were diagnosed as GBM, of which 3 were subtyped as gliosarcoma and 6 as giant cell GBM. There was a 95% (338/354) consensus with regard to diagnosis of GBM versus non-GBM amongst the three neuropathologists. The median age of patients with confirmed GBM was 56 years of age (range 19-79) (Supplemental Table S2).

### ***Frequency of GBM with an oligodendroglioma-like component***

The criteria for GBM-O were met in 52 (15%) samples, an expected frequency [12,29,37]. Sub-typing of centrally confirmed GBM, including GBM-O, resulted in a 2:1 agreement for 24 cases, of which 16 overlapped with the debated cases for GBM versus non-GBM. In the group classified as GBM-O 2 of 5 were considered as AOA and 2 as AO, by one of the neuropathologists. The median age of patients with GBM-O was lower than that of the other GBM patients (53y vs 56y,  $p=0.02$ ) (Supplemental Table S2).

### ***GBM-O encompass a pathogenetically heterogeneous group***

Evaluation of important prognostic molecular markers revealed the same frequency of *MGMT* methylation in GBM-O (47%, 16/34) versus the remaining GBM (46%, 60/131) (Table 2). Furthermore, combined loss of 1p/19q, a hallmark of oligodendroglioma tumors and associated with better prognosis in anaplastic glioma [35], was a rare event, observed in a single GBM-O, confirmed by aCGH, and one GBM (Fig. 2, Table 2).

Next we investigated if GBM-O exhibit a particular pathogenetic make-up. Mutations of the *IDH1* gene that are associated with better outcome in GBM [40] were significantly enriched in GBM-O (6/32, 19%) as compared to the remaining GBM (3/98,

3%;  $p=0.002$ ). Similarly, *EGFR* amplification that has been associated with older age and potentially worse outcome, was present in 71% of GBM-O (22/31) and 48% of the remaining GBM (48/100) ( $p=0.03$ ). *IDH1* and *EGFR* alterations were mutually exclusive as reported before [40]. Intriguingly, of 31 GBM-O for which this genetic information was available, 6 carried the IDH1R132H mutation, 22 displayed an *EGFR* amplification, and only three had neither alteration. The presence of an *IDH1* or *IDH2* hot-spot mutation other than IDH1R132H was excluded by direct sequencing in these 3 cases. The notion that the GBM-O phenotype identifies at least two pathogenetically distinct subgroups is further supported by classification according to the four gene expression based subtypes proposed by Verhaak *et al.* [36]. Of 14 evaluable GBM-O 5 grouped with the proneural, 6 with the classical, 2 with the mesenchymal, and 1 with the neural GBM-subtypes. In accordance with the reported mutation pattern of the 4 subgroups, all GBM with an *IDH1* mutation were in the proneural group, while most *EGFR* amplified and *EGFRvIII* positive GBM were in the classical subgroup (Fig. 3).

### ***Survival of patients with GBM-O is not different from those with GBM***

Patients with non-GBM pathology (15/354, 4%) were enriched in the patient group with overall survival (OS) exceeding 24 months (9/64, 14%), as compared to the short survival group ( $\leq 9$  months, 1/101), and the intermediate group (5/189, 3%) ( $p<0.001$ , chi-square-test) (Fig. 1). Subsequently, only patients with confirmed GBM ( $n=339$ ) are included for further analysis of morphologic features and outcome. There was no difference in OS between GBM and GBM-O (logrank test,  $p=0.48$ ). Stratification by age ( $\leq 50$ , 51-60 or  $>60$ ) ( $p=0.55$ ) or *MGMT* methylation status ( $p=0.27$ ) did not differentiate

survival in the two subgroups. When analyzing the GBM-O separately per randomized treatment arm, survival was not different for GBM-O in either arm (TMZ/RT→TMZ arm,  $p=0.81$ ; RT-only arm,  $p=0.14$ ) (Fig. 4). The respective values for progression-free survival were similar ( $p=0.97$ , TMZ/RT→TMZ;  $p=0.2$ , RT). Likewise, using less strict criteria, just presence of any oligodendroglioma-like component, did not show any association with outcome in either of the two treatment arms (Table 1). The apparent enrichment of patients with presence of any oligodendroglioma-like component in the long survivor group as visualized in Figure 2 is due to inclusion of patients where GBM was not confirmed.

### ***Associations of histopathological features with tumor genetics***

The MIB-1 labeling index was significantly higher in *MGMT* methylated GBM with a mean index of 38% ( $n=69$ ) as compared to 30% in *MGMT* unmethylated tumors ( $n=84$ ) ( $p=0.0015$ ). A trend for a higher MIB-1 labeling index was associated with *IDH1* mutations and *EGFR* amplifications ( $p=0.07$ ,  $p=0.09$ ). No significant association was observed between any morphologic feature and the *MGMT* methylation status.

### ***Associations of tumor genetics and outcome***

None of the genetic alterations investigated here was associated with a prognostic or a predictive value with the exception of *MGMT* methylation as previously reported (Supplementary Table S5) [32,38]. Mutations of *IDH1* were rare in confirmed GBM (9/130; 7%, for which this information was available) as expected [25] and similarly distributed between the treatment arms (5, RT; 4, RT&TMZ), with 5 of 8 assessable

cases being *MGMT* methylated. These small numbers do not allow appropriate assessment of the prognostic value of IDH1 mutations ( $p=0.7$ , Supplementary Fig. S2). The patterns of genetic alterations and outcome are displayed in Figure 1.

***Presence of pseudopalisading necroses (PPN) is associated with a treatment effect of TMZ***

Correlation of the distinct morphologic features assessed, such as type of necrosis, vascular pattern, and cell differentiation, and including the MIB-1 (Ki67) labeling index (Supplementary Fig. S1), identified PPN as the only morphologic feature associated with outcome (Table 1). PPN was present in 63% of all GBM (212/339) and associated with a treatment effect (Fig. 5, Table 1). Addition of TMZ to RT was beneficial in the patient cohort exhibiting PPN ( $p=0.0002$ ), while no such effect was present in the absence of PPN ( $p=0.86$ ) (Fig. 5a). Peto's interaction test was significant ( $p=0.026$ , Fig. 5b), and borderline non significant in a Cox interaction model adjusted for known clinical prognostic factors ( $p=0.087$ , Supplemental Table S3) not accounting for *MGMT* that was available only for a subset of 165 mostly resected tumors (Supplementary Table S1). This suggests that indeed PPN may identify a subgroup of chemo-sensitive GBM. The incidence of PPN was lower in patients with biopsy only (46% vs 65.4%,  $p=0.01$ ), while no association with age was observed ( $p=0.15$ ). To exclude a bias of potential underestimation of PPN in stereotactic biopsies resulting from the small sample size, and the fact that biopsy only by itself is an unfavourable prognostic factor, the analyses were repeated in patients who underwent a tumor resection. Peto's test was significant ( $p=0.040$ , Supplementary Fig. S3) and the adjusted Cox interaction model including

*MGMT* was borderline non significant ( $p=0.063$ , Supplementary Table S4). A similar treatment effect of PPN was observed for PFS ( $p<0.0001$ ) in the TMZ-arm, while there was a trend in the RT arm ( $p= 0.078$ ).

## **Discussion**

The present study was performed to assess prognostic significance of morphological features of GBM in the registration trial for temozolomide, with a focus on GBM-O. Classification of GBM was in high concordance ( $>95\%$ ) between the 59 centers and central review. Expectedly, reclassification as a non-GBM histology was significantly enriched among long-term survivors (Fig. 2). The trial analyses and respective reports were on an intention-to-treat basis [32], hence include the patients with non-GBM histology.

Identification of unambiguous morphologic features with a prognostic or predictive value within GBM would be clinically valuable as such markers could be easily implemented in routine histopathologic diagnostics. The recognized phenotypical GBM variants, giant cell GBM and gliosarcoma are rare (6,  $<2\%$  and 3,  $<1\%$  in this study) [15] precluding reliable assessment of a potential prognostic significance when patients are treated with the current standard of care. Evaluation of the prognostic value of an oligodendroglioma-like component in an otherwise classic GBM revealed no association with a more favorable disease course in either of the two treatment arms, in contrast to previous studies on GBM-O [9,12,16,18,29]. This discrepancy might be explained by the fact that most studies were performed in the pre-TMZ chemotherapy era. GBM-O, as defined in this report, seem to benefit similarly from chemoradiotherapy, in line with the

identical *MGMT* methylation frequency compared to other GBM that differs from frequencies reported for AO and AOA of over 70% [5,20,27,39]. Further, the delineation of “pure” GBM versus GBM-O, AOA and AO is difficult, reflected in variable frequencies of reported 1p/19q co-deletions in these studies ranging from 0 to over 20% for the GBM-O sub-group [9,12,13,16,18,29].

This study uncovered that GBM-O encompasses at least two distinct patho-genetic subgroups, characterized either by *EGFR* amplifications or *IDH1* mutations, and further supported by respective expression-based classification (Fig. 3). GBM-O, as defined here may in part overlap with the small cell variant of GBM with high cellularity, diffuse more or less monotonous growth and relatively small, partly rounded nuclei that is known for increased *EGFR* amplification frequencies [12,18]. Conversely, GBM with *IDH* mutations are now recognized as a distinct subtype with a different pathogenetic/epigenetic origin, evolving from lower grade glioma with high frequencies of *IDH* mutations, characteristic for secondary GBM [1,23,40]. Interestingly, *IDH* mutant gliomas are associated with a DNA hypermethylation phenotype [24]. This association has recently also been reported in leukemia, identifying a new prognostic subtype, and mechanistically linking aberrant metabolism (onco-metabolite) with epigenetic deregulation [6,26]. Our finding that recognition of an oligodendroglioma-like phenotype in otherwise classic GBM associates two completely different genetic/epigenetic GBM subtypes was a surprise and questions the clinical utility of morphologic identification of GBM-O. The introduction in the 2007 WHO classification of high-grade malignant oligoastrocytic tumors with necrosis as GBM-O [14] has led to substantial controversy among pathologists [30], and will certainly have to be re-visited given the recently discovered distinct patho-genetic/epigenetic evolution. Determination of oncogenetic



events such as IDH status and 1p/19q co-deletions provide a more promising tool for robust and reproducible (sub)classification of malignant gliomas [8].

Evaluation of distinct morphologic features in this homogenously treated patient population identified PPN as potentially associated with benefit from combined chemo-radiotherapy. Presence of PPN may reflect the tumor milieu including the tumor vascularisation type which may have an effect on drug perfusion and thereby on response to chemotherapy. Pseudopalisades are enriched for hypoxic and apoptotic tumor cells, with a lower relative proliferation index, and are frequently associated with a central degenerating or thrombosed vascular lumen [2,28]. Tumor-associated vascular injury has been associated with factors released from glioma cells after genetic alterations such as *EGFR* amplifications, or cellular stress conditions such as hypoxia [3,28]. Based on comprehensive analysis of PPN in human GBM and experimental models, it has been hypothesized that pseudopalisades comprise hypoxic tumor cells migrating away from dysfunctional vessels [2,28]. However, the presence of PPN does not directly correlate with hypoxia as suggested by gene expression profiles available for 50 patients of this cohort [21,22]. No correlation was observed with the previously identified hypoxia-induced gene expression signature, while the *EGFR* expression signature (G25) was significantly associated with presence of PPN ( $p=0.02$ ). Evaluation of associations of PPN with previously identified expression signatures in appropriately powered studies may indicate underlying molecular mechanisms that merit further analysis for improvement of therapy. Respective hypotheses may be tested in the database of 'The Cancer Genome Atlas' (TCGA) once the morphologic information will become publically available [36]. In contrast to our study, Homma *et al.* [12] reported an

association of presence of any type of necrosis with worse outcome. This discrepancy may be explained by the fact that all these patients were treated before the TMZ era (before 1994) and likely received RT alone.

This study has shown that systematic combined morphologic and molecular characterization of tumor samples of patients enrolled in clinical trials is instrumental for validating and identifying new prognostic and predictive factors that will have an impact on clinical practice. This was an exploratory study requiring validation in an independent data-set of a homogenous patient population treated with combined chemo-radiotherapy. The limited numbers of samples available for molecular analyses unfortunately reduced the power of the study, once more emphasizing the importance to collect sufficient tissues for all patients enrolled in clinical trials.

### **Conflict of Interest**

MEH is an advisor to MDxHealth. MEH, MW, MJvdB, ROM, and RS have an advisory role and have received honoraria from MSD. CH and AvD have a licensing agreement with Dianova GmbH.

### **Acknowledgments**

We thank all patients who participated in the study and provided informed consent for translational research on their tumor tissues. We acknowledge the great contributions of local pathologists, the physicians and nurses taking care of the patients, and thank Solange Gros and Sylviane Trepey for excellent technical support.

Translational research in this study was supported by the Swiss National Science Foundation 3100A0\_122557/1 (MEH), the Amadéo and Nélia Barletta Foundation (MEH, RS), the Jacqueline Seroussi Foundation (MEH), and the EORTC (TRF/04/01, TRF/02/03). Additional support was given by grants from the National Cancer Institute (5U10 CA11488-30 through 2U10 CA011488-41; Bethesda, Maryland, USA) and by the EORTC Charitable trust. The content of this manuscript is solely the responsibility of the authors and does not necessarily reflect the official views of the National Cancer Institute.

## References

- 1 Balss J, Meyer J, Mueller W et al (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. *Acta Neuropathol* 116:597-602
- 2 Brat DJ, Castellano-Sanchez AA, Hunter SB et al (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. *Cancer Research* 64:920-927
- 3 Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. *Lab Invest* 84:397-405
- 4 Capper D, Weissert S, Balss J et al (2009) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. *Brain Pathol* 20:245-254
- 5 Dong SM, Pang JC, Poon WS et al (2001) Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. *J Neuropathol Exp Neurol* 60:808-816
- 6 Figueroa ME, Abdel-Wahab O, Lu C et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 18:553-567
- 7 Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. *Lancet Oncol* 9:29-38
- 8 Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. *Acta Neuropathol* 120:707-718
- 9 He J, Mokhtari K, Sanson M et al (2001) Glioblastomas with an oligodendroglial component: a pathological and molecular study. *J Neuropathol Exp Neurol* 60:863-871

- 10 Hegi ME, Diserens A-C, Bady P et al (2011) Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib - A Phase II trial. *Mol Cancer Ther* 11:102-112
- 11 Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. *N Engl J Med* 352:997-1003
- 12 Homma T, Fukushima T, Vaccarella S et al (2006) Correlation among pathology, genotype, and patient outcomes in glioblastoma. *J Neuropathol Exp Neurol* 65:846-854
- 13 Ichimura K, Pearson DM, Kocialkowski S et al (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. *Neuro Oncol* 11:341-347
- 14 Kleihues P, Burger PC, Aldape KD et al (2007) Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) *WHO Classification of Tumours of the Central Nervous System*. International Agency for Research on Cancer (IARC), Lyon, pp 33-46
- 15 Kleihues P, Cavenee WK (2000) *Pathology & Genetics. Tumours of the nervous system*. IARC Press, Lyon
- 16 Kraus JA, Lamszus K, Glesmann N et al (2001) Molecular genetic alterations in glioblastomas with oligodendroglial component. *Acta Neuropathol* 101:311-320
- 17 Lambiv WL, Vassallo I, Delorenzi M et al (2011) The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. *Neuro Oncol* 13:736-747
- 18 Miller CR, Dunham CP, Scheithauer BW et al (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. *J Clin Oncol* 24:5419-5426
- 19 Mirimanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. *J Clin Oncol* 24:2563-2569
- 20 Möllemann M, Wolter M, Felsberg J et al (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. *Int J Cancer* 113:379-385

- 21 Murat A, Migliavacca E, Gorlia T et al (2008) Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. *J Clin Oncol* 26:3015-3024
- 22 Murat A, Migliavacca E, Hussain SF et al (2009) Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. *PLoS ONE* 4:e5947
- 23 Nobusawa S, Watanabe T, Kleihues P et al (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. *Clin Cancer Res* 15:6002-6007
- 24 Noshmehr H, Weisenberger DJ, Diefes K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 17:419-420
- 25 Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. *Brain Tumor Pathol* 28:177-183
- 26 Prensner JR, Chinnaiyan AM (2011) Metabolism unhinged: IDH mutations in cancer. *Nat Med* 17:291-293
- 27 Riemenschneider MJ, Hegi ME, Reifenberger G (2010) MGMT promoter methylation in malignant gliomas. *Target Oncol* 5:161-165
- 28 Rong Y, Durden DL, Van Meir EG et al (2006) 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. *J Neuropathol Exp Neurol* 65:529-539
- 29 Salvati M, Formichella AI, D'Elia A et al (2009) Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases. *J Neurooncol* 94:129-134
- 30 Scheithauer BW, Fuller GN, Vandenberg SR (2008) The 2007 WHO Classification of Tumors of the Nervous System: Controversies in Surgical Neuropathology. *Brain Pathology* 18:307-316
- 31 Seiz M, Tuettenberg J, Meyer J et al (2010) Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. *Acta Neuropathol* 120:261-267
- 32 Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in

glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 10:459-466

- 33 Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352:987-996
- 34 van den Bent MJ, Brandes AA, Rampling R et al (2009) Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. *J Clin Oncol* 27:1268-1274
- 35 van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. *J Clin Oncol* 24:2715-2722
- 36 Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 17:98-110
- 37 Vordermark D, Ruprecht K, Rieckmann P et al (2006) Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). *BMC Cancer* 6:247
- 38 Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network. *J Clin Oncol* 27:5743-5750
- 39 Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. *J Clin Oncol* 27:5874-5880
- 40 Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. *N Engl J Med* 360:765-773

## Figure Legends

**Fig. 1.** Examples of histology in two tumors diagnosed as glioblastoma with oligodendroglioma-like component. **a** Area showing diffuse highly cellular and monotonous growth of tumor cells with a dense chromatin pattern, perinuclear halo-formation and chickenwire architecture of the microvasculature. **b** Highly cellular area showing rounded tumor cell nuclei with dense chromatin pattern and perinuclear halo-formation. See Material and Methods for the definitions used in the present study for recognition of oligodendroglioma-like component in glioblastoma. Arrowheads in **a**: mitotic figures; arrowhead in **b**: florid microvascular proliferation. **a, b**: Hematoxylin-and-Eosin staining, original magnification x200.

**Fig. 2.** Patterns of genetic alterations, diagnosis and outcome. Patient data for 175 cases with 3/6 genetic tests available were ordered according to overall survival (OS). Many features are rare, such as GBM subtypes, or genetic alterations like *IDH1* mutations. The visualization allows identification of patterns of genetic or clinical features that are enriched in either the short survival group or the long-term survival group. Gene amplification is represented in red (*CDK4*, *MDM2*, *EGFR*) and deletions in dark blue (co-deletion of 1p/19q). Mutation of *IDH1* is represented in red, and *MGMT* methylated in grey, unmethylated in black. OS in months: light green short survival group ( $\leq 9$  months); green, intermediate survival group ( $>9$  and  $<24$  months), dark green, long-term survival group ( $\geq 24$  months). Age  $<50$  years is represented in grey, 50 to 60 years, dark gray, and  $>60$  years in black; female, red, male blue. Diagnosis as GBM, pink; GBM-O, purple; Gliosarcoma, yellow; giant cell GBM (GC-GBM), orange; AOA, blue; other non-



GBM diagnosis, green. Concordance of reviewers 3:0 for subtype (Con\_subT) or diagnosis (Con\_diagn) in dark blue; concordance 2:1, blue; diagnosis by Canadian central review, light blue. Diagnosis of non-GBM is indicated in black. No information, white for all criteria. The associated table below shows the respective numbers. *EGFRvIII* information was available for only 56 cases and is not included in the upper panel.

**Fig. 3.** Gene expression based classification and GBM subtype.

For 57 patients gene expression data, including for *EGFRvIII*, was available from frozen tumor tissue [21]. The tumor samples were classified according to the algorithm proposed by Verhaak et al. [36] into classic, mesenchymal, neural, and proneural GBM. The samples are ordered by the gene expression based classification, followed by diagnostic subtype, Gliosarcoma (GS), GBM-O, and GBM. The respective patho-genetic information and clinical information is the same as in Figure 1. The enrichment of specific pathogenetic alterations, such as IDH1 mutations in the proneural and *EGFR* amplification & *EGFRvIII* expression in the classical subtype, is in accordance with the report by Verhaak et al. [36]. Gene amplification is represented in red (*CDK4*, *MDM2*, *EGFR*) and deletions in dark blue (co-deletion of 1p/19q). *EGFRvIII* expression determined by qRT-PCR is depicted in yellow. Mutation of IDH1 is represented red, and *MGMT* methylated in grey, unmethylated in black. OS in months: light green short survival group ( $\leq 9$  months); green, intermediate survival group ( $>9$  and  $< 24$  months), dark green, long-term survival group ( $\geq 24$  months). Age  $<50$  is represented in grey, 50 to 60, dark grey, and  $>60$  years in black; female, red, male blue. Diagnosis as GBM, pink; GBM-O, purple; Gliosarcoma (GS), yellow. Concordance of reviewers 3:0 for

subtype (Con\_subT) or diagnosis (Con\_diagn) in dark blue; concordance 2:1, blue; diagnosis by Canadian central review, light blue. No information, white for all criteria.

**Fig. 4.** GBM-O have no better prognosis than all other GBM.

Kaplan-Meier curves show the OS of GBM vs GBM-O in the RT arm (log-rank test  $p=0.136$ ) (A) and the TMZ/RT→TMZ arm ( $p=0.814$ ) (B).

**Fig. 5.** Presence of pseudo-palisading necrosis is associated with a treatment effect. **a** The Kaplan-Meier curves visualize the overall outcome of the patients in presence or absence of pseudo-palisading necrosis (PPN). In presence of PPN there is a treatment effect (RT vs TMZ/RT→TMZ  $p=0.002$ ), while in absence of PPN, no such difference is observed (RT versus TMZ/RT→TMZ,  $p=0.86$ ). **b** Forest Plot and Peto's test of interaction between PPN and treatment for OS in all confirmed GBM. Peto's test was significant ( $p=0.03$ ) indicating that treatment effects differ significantly as a function of PPN.

**Table 1. Morphologic features of confirmed GBM and OS (N=339)**

Subsample Characteristics							
	Treatment			P-value Fisher	Prognostic value for	Prognostic value for	Prognostic value for
	RT	TMZ/RT	Total		Overall Survival	Overall Survival	Overall Survival
	(N=173) N (%)	(N=166) N (%)	(N=339) N (%)		P-value Pooled	P-value RT	P-value TMZ/RT
<b>Diagnosis</b>							
Glioblastoma	145 (83.8)	133 (80.1)	278 (82.0)	0.69			
GBM-O	25 (14.5)	27 (16.3)	52 (15.3)				
Giant cell glioblastoma	2 (1.2)	4 (2.4)	6 (1.8)				
Gliosarcoma	1 (0.6)	2 (1.2)	3 (0.9)				
<b>GBM confirmed</b>							
GBM	148 (85.5)	139 (83.7)	287 (84.7)	0.65	0.48	0.14	0.81
GBM-O	25 (14.5)	27 (16.3)	52 (15.3)				
<b>NECROSIS-Large ischaemic type</b>							
No	34 (19.7)	23 (13.9)	57 (16.8)	0.19	0.79	0.18	0.20
Yes	139 (80.3)	143 (86.1)	282 (83.2)				
<b>NECROSIS-Pseudopalisading</b>							
No	62 (35.8)	65 (39.2)	127 (37.5)	0.58	0.27	0.32	<b>0.03</b>
Yes	111 (64.2)	101 (60.8)	212 (62.5)				
<b>NECROSIS-Thrombosed vessels</b>							
No	27 (15.6)	28 (16.9)	55 (16.2)	0.77	0.48	0.99	0.40
Yes	146 (84.4)	138 (83.1)	284 (83.8)				
<b>Microvascular proliferation</b>							
No	2 (1.2)	4 (2.4)	6 (1.8)	0.44	0.80	0.98	0.92
Yes	171 (98.8)	162 (97.6)	333 (98.2)				
<b>Perivascular lymph</b>							
No	133 (76.9)	128 (77.1)	261 (77.0)	0.90	0.89	0.39	0.40
Yes	38 (22.0)	35 (21.1)	73 (21.5)				
Missing	2 (1.2)	3 (1.8)	5 (1.5)				
<b>Oligodendroglioma-like component</b>							
No	129 (74.6)	120 (72.3)	249 (73.5)	0.80	0.24	0.29	0.52
Yes	44 (25.4)	44 (26.5)	88 (26.0)				
Missing	0 (0.0)	2 (1.2)	2 (0.6)				
<b>Sarcomatous comp</b>							
No	167 (96.5)	157 (94.6)	324 (95.6)	0.57	0.15	0.16	0.34
Yes	5 (2.9)	7 (4.2)	12 (3.5)				
Missing	1 (0.6)	2 (1.2)	3 (0.9)				
<b>Multinucleated giant cells</b>							
No	137 (79.2)	124 (74.7)	261 (77.0)	0.44	0.43	0.78	0.38
Yes	36 (20.8)	40 (24.1)	76 (22.4)				
Missing	0 (0.0)	2 (1.2)	2 (0.6)				
<b>Gemistocytic cells</b>							
No	124 (71.7)	123 (74.1)	247 (72.9)	0.54	0.41	0.70	0.65
Yes	49 (28.3)	41 (24.7)	90 (26.5)				
Missing	0 (0.0)	2 (1.2)	2 (0.6)				



Subsample Characteristics							
	Treatment			P-value Fisher	Prognostic value for	Prognostic value for	Prognostic value for
	RT (N=173)	TMZ/RT (N=166)	Total (N=339)		Overall Survival P-value	Overall Survival P-value	Overall Survival P-value
	N (%)	N (%)	N (%)		Pooled	RT	TMZ/RT
Other Prominent patterns							
No	157 (90.8)	141 (84.9)	298 (87.9)	0.21	0.82	0.13	0.75
Yes	14 (8.1)	20 (12.0)	34 (10.0)				
Missing	2 (1.2)	5 (3.0)	7 (2.1)				
MIB-1							
Median	30.0	30.0	30.0	0.08 <sup>a</sup>	0.13	0.65	0.24
Mean (SD)	32.72 (17.81)	36.40 (18.26)	34.53 (18.10)				
Range	5.0 - 80.0	5.0 - 90.0	5.0 - 90.0				
N obs	156	150	306				



<sup>a</sup>Wilcoxon rank sum test

**Table 2 Tumor genetics of GBM-O versus GBM**

Overall Cases in Central Review	Confirmed GBM (%)	GBM-O (%)	GBM (%)	p-value <sup>a</sup>
<b>Alterations</b>				
<b>methMGMT</b>	76/165 (46)	16/34 (47)	60/131 (46)	1.00
<b>IDH1 mut</b>	9/130 (7)	<b>6/32 (19)</b>	3/98 (3)	<b>0.007</b>
<b>Co-del 1p/19q</b>	2/137 (1)	1/31 (3)	1/106 (1)	0.4
<b>EGFR amp</b>	70/131 (53)	<b>22/31 (71)</b>	48/100 (48)	<b>0.038</b>
<b>CDK4 amp</b>	24/131 (18)	7/29 (24)	17/102 (17)	0.42
<b>MDM2 amp</b>	13/131 (10)	4/30 (13)	9/101 (9)	0.49

<sup>a</sup>Fisher exact test






All Diagnosable Tumors in Central Review LN (n=354; including non-GBM)


GBM-O (52/354, 15%)	14/101 (14%)	29/189 (15%)	9/64 (14%)
nonGBM (15/354, 4%)	1/101 (1%)	5/189 (3%)	9/64 (14%)
O-comp (94/345, 27%)	20/101 (20%)	53/185 (29%)	21/59 (36%)
PPN (215/349, 62%)	60/102 (59%)	115/208 (55%)	39/62 (63%)

Genetics, all Info Available (including non-GBM)


IDH1 mt (12/160, 8%)	1/38 (3%)	7/84 (8%)	4/38 (3 nonGBM)
Codel 1p/19q (2/168, 1%)	0/39	2/94 (2%)	0/94
EGFR amp (83/166, 50%)	22/40 (55%)	43/89 (48%)	18/37 (49%)
MGMT_m (103/226, 46%)	20/50 (40%)	47/129 (36%)	36/47 (77%)
CDK4 amp (27/164, 16%)	6/38 (16%)	16/90 (18%)	5/36 (14%)
MDM2 amp (17/162, 11%)	3/38 (8%)	11/88 (13%)	3/26 (8%)
EGFRvIII (18/56, 30%)	7/18 (39%)	6/30 (17%)	5/13 (38%)









a



b



**a**



\*95% CI everywhere

**b**